Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
Dr. Hirschman has provided to ADVR a summary of the published paper. In his summary, Dr. Hirschman states:
"The in vitro findings reveal that Reticulose significantly inhibits the replication of HIV in cell culture systems. Most important, Reticulose stimulates the immune system to produce a distinctive set of substances called chemokines (cytokines). Reticulose belongs to a recently discovered group of chemical structures called peptide nucleic acids (PNAs). PNAs are newly appreciated molecules consisting of both amino acids and nucleic acids (part protein and part gene) that already have been shown to have interesting properties; for example, they are very stable and have anti-sense activity. Reticulose, a non-toxic PNA, appears to stimulate the immune system to go into a continuous repair mode to prevent HIV from invading cells. Reticulose is compatible in vitro with drugs currently used to treat AIDS including the nucleoside, analogues azidothymidine (AZT) and lamivudine (3TC) and the protease inhibitor, saquinavir. Reticulose could function as a broad antiviral drug operating via the immune system and may in fact be useful in the therapy of other conditions that require immune surveillance, such as neoplasias."
The information contained herein with respect to the study performed by Dr. Hirschman has been supplied by Dr. Hirschman. This press release contains a summary of information delivered by: Dr. Hirschman to ADVR only and is qualified in its entirety by and should be read in conjunction with the published paper.
CONTACT: William Bregman, Advanced Viral Research Corp., 954-458-7636
Copyright (c) 1996/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
960828
PR960827
Copyright © 1996 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .